Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 28, 2026˜The œmedical letter on drugs and therapeutics/˜The œmedical letter

Inebilizumab (Uplizna) for Myasthenia Gravis

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates ine bilizumab effects on generalized myasthenia gravis, indicating potential benefits for affected adults.

Key Points

  • To assess the effectiveness of inebilizumab in treating generalized myasthenia gravis in adults with specific antibodies.
  • FDA approval for intravenous treatment of generalized myasthenia gravis in adults
  • Inclusion of anti-acetylcholine receptor and anti-muscle-specific tyrosine kinase antibodies as targets
  • Comparison with other approved FcRn blockers
  • FDA approval confirms positive outcomes for generalized myasthenia gravis patients
  • Inebilizumab, an anti-CD19 antibody, shows efficacy in reducing symptoms
  • Approval aligns with existing treatments such as rozanolixizumab and nipocalimab

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a40b96161bb0a67205c59dfhttps://doi.org/10.58347/tml.2026.1758d
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rozanolixizumab (Rystiggo) for Myasthenia Gravis2024
  2. 2Real-World Efficacy and Safety of Inebilizumab in Generalized Myasthenia Gravis (P9-9.014)2026
  3. 3Rescue Treatment of Inebilizumab in Refractory Myasthenia Gravis: A Case Report (P11-9.004)2026
  4. 4Management of Exacerbations and Rescue Therapy2026 · 1 citations
  5. 5Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)2026